Alkem Laboratories Ltd
Alkem Laboratories Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27. - Domestic market remains core; strategic initiatives support sustained momentum. - Non-U.S. Alkem expects continued strong growth across India, U.S., and key international markets supported by new product launches. - India business is forecasted to outperform the market by 100 to 150 basis points with a double-digit growth outlook for FY27. - U.S.
From Alkem Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27.
- Domestic market remains core; strategic initiatives support sustained momentum.
- Non-U.S. export markets projected to grow at high teens to around 20% annually.
- U.S. CDMO plant: Operationally just started; expected revenue ramp-up to INR300 crores annual run rate in 12-18 months.
- MedTech business: Break-even anticipated in FY28, with moderate operational expenses during ramp-up.
- Enzene business (U.S.): Revenues around INR70-80 crores expected in FY26, with INR50 crores quarterly opex; breakeven targeted in 12-18 months.
- Overall, double-digit growth is maintained across geographies with new launches contributing to expansion.
Profitability & Margins
See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The U.S. CDMO plant recently became operational, with ongoing ramp-up expected to reach full capacity and INR 300 crores revenue run-rate in 12 to 18 months. Future expansion investments will be considered based on opportunity and demand.
- Medtech business is in investment phase, with planned expenses on product filings and approvals for new markets; breakeven expected by FY '28.
- No immediate large-scale capex indicated beyond current operations, though management remains open to additional investments if strategic opportunities arise.
- India remains the core market with continuous brand/market investments; strategic acquisitions considered when right opportunities emerge.
- R&D investments continue, expected to be around 4%-5% of revenues, with filings mostly concentrated in Q4.
- Overall, planned investments and opex for new businesses (CDMO, Medtech) are factored into margin and growth guidance.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The newly operational U.S. CDMO plant has just started and has an estimated order book expected to generate around INR 300 crores in revenue over the next 12 to 18 months.
- Current quarterly revenues from the U.S. CDMO business are around INR 15-20 crores, with operating expenses at approximately INR 50 crores per quarter as ramp-up continues.
- Management is closely monitoring the order book and plant output, with potential for further investment if demand warrants it.
- No specific number of projects or detailed order backlog figures were disclosed, as Alkem does not provide project-level details publicly.
- Enzene U.S. plant expects to reach an annualized revenue run-rate of INR 300 crores in 12-18 months from the current operations.
- Management is optimistic about ramp-up and scaling opportunities but cautious, awaiting better visibility from current bookings and order flow.
Alkem Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.6K Cr, net profit ₹251 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alkem Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharmaceutical Industries Ltd (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Alkem Laboratories Ltd Q2 FY26 results?
India business growth: Expected to continue strong with at least 100-150 bps outperformance over the Indian Pharmaceutical Market (IPM) growth of ~8-8.5% for H2 FY26 and FY27. - Domestic market remains core; strategic initiatives support sustained momentum. - Non-U.S. Alkem expects continued strong growth across India, U.S., and key international markets supported by new product launches. - India business is forecasted to outperform the market by 100 to 150 basis points with a double-digit growth outlook for FY27. - U.S.
What is Alkem Laboratories Ltd share price analysis?
Alkem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 27.9 with a market cap of ₹68,110 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alkem Laboratories Ltd planning capital expenditure?
The U.S.
Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.